|BGMD -- USA Stock|| |
USD 0.048 0.002 4.00%
Dr. Stelios B. Papadopoulos, Ph.D., is an Independent Director of BG Medicine, Inc. He has served as Chairman of Fondation Sant, a private charitable foundation whose mission is to provide support for research and education in the life sciences. Dr. Papadopoulos served as Vice Chairman of Cowen and Company, LLC from 2003 until 2006 and as Managing Director from 2000 until 2003. While at Cowen and Company, LLC, he worked as an investment banker focused on the biotech and pharmaceutical sectors. Prior to joining Cowen and Company, LLC, he worked as an investment banker at PaineWebber, Incorporated, from 1987 to 2000, where he was Chairman of PaineWebber Development Corporationration, a PaineWebber subsidiary focusing on biotechnology from 1996 to 2000. Dr. Papadopoulos is a cofounder and Chairman of the Board of Exelixis, Inc. Dr. Papadopoulos currently serves as chairman of the board of Regulus Therapeutics, Inc. and Biogen Inc. and he is a member of the board of directors of Joule Unlimited, Inc. During the past five years, he also served on the board of directors of Anadys Pharmaceuticals, Inc., and Cellzome, Inc. . He is also a member of the board of visitors of Duke University School of Medicine and the board of Global Advisors of the Duke Institute of Health Innovation
Age: 67 Director Since 2012 MBA
Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University.
Stelios Papadopoulos Latest Insider Activity
The company has return on total asset (ROA)
of (75.95) %
which means that it has lost $75.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (902.64) %
meaning that it created substantial loss on money invested by shareholders.
BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG Medicine operates under Diagnostics Research classification in USA and traded on OTC Market. It employs 5 people.BG Medicine (BGMD) is traded on OTC Market in USA. It is located in MASSACHUSETTS, U.S.A and employs 5 people. BG Medicine is listed under Pharmaceutical Products category by Fama And French industry classification.
BG Medicine Leadership Team
|James Connor, Director|
|Harry Wilcox, Director|
|Stelios Papadopoulos, Director, MBA|
|Aram Adourian, SVP, Ph.D|
|Stephen Hall, CFO, MBA|
|Jeffrey Luber, Director, MBA|
|Paul Sohmer, CEO|
|Noubar Afeyan, Founder|
|James OConnor, Director|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on BG Medicine. What is your opinion about investing in BG Medicine? Are you bullish or bearish?
and pair trading evaluation for BG Medicine and NantKwest
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return